Anzeige
Mehr »
Login
Dienstag, 18.05.2021 Börsentäglich über 12.000 News von 658 internationalen Medien
Suchen Sie auch nach Fosterville South (A2QJKK)? Hier gibt´s News!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 858523 ISIN: JP3256000005 Ticker-Symbol: KY4 
Stuttgart
17.05.21
08:02 Uhr
25,000 Euro
+0,400
+1,63 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
KYOWA KIRIN CO LTD Chart 1 Jahr
5-Tage-Chart
KYOWA KIRIN CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
24,40025,40017.05.

Aktuelle News zur KYOWA KIRIN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.05.Kyowa Kirin wins European nod for self-administered CRYSVITA1
14.04.Ardelyx collaboration partner Kyowa Kirin initiates late-stage tenapanor trial in japan3
29.03.Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-0024
KYOWA KIRIN Aktie jetzt für 0€ handeln
29.03.Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6%2
29.03.Cerecor Inc.: Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-0021
25.03.Twist Bioscience and Kyowa Kirin team up for GPCR antibody discovery12
04.03.Kyowa Kirin Responds to the National Institute for Health and Care Excellence (NICE) Decision to Not Provide People Living With Certain Rare Blood Cancers Access to POTELIGEO (mogamulizumab)294Adults with two very rare forms of non-Hodgkin lymphoma will not have access to an innovative systemic treatment following NICE's decision to not recommend mogamulizumab for routine use in the NHS....
► Artikel lesen
18.02.Provention Bio inks China deal for autoimmune program; Kyowa Kirin releases positive topline data in atopic dermatitis2
09.12.20News briefing: Assembly Bio scraps microbiome programs; InveniAI, Kyowa Kirin expand partnership to focus on novel targets14
01.12.20Helsinn Healthcare S.A.: Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific's rare disease therapy area427Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific's rare disease therapy area Lugano, Switzerland, and Singapore...
► Artikel lesen
13.10.20Kyowa Kirin International: Kyowa Kirin Presents New Data on Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients Who Have Blood Involvement302Results of data analysis from the MAVORIC trial could help improve clinical management of the disease, data presented today at the 16th European Association of Dermato Oncology (EADO) Congress Kyowa...
► Artikel lesen
02.10.20Kyowa Kirin Announces European Commission (EC) Approval of CRYSVITA (burosumab) for the Treatment of X-Linked Hypophosphataemia (XLH) in Older Adolescents and Adults455More people in Europe are now eligible for treatment with CRYSVITA, the only therapy that targets the underlying pathophysiology of XLH, a rare, life-long genetic disease that causes abnormalities...
► Artikel lesen
09.07.20Mylan, Fujifilm Kyowa Kirin Receive FDA Approval Of Hulio1.150CANONSBURG (dpa-AFX) - Pharmaceutical companies Mylan N.V. (MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced Thursday that the U.S. Food and Drug Administration (FDA) has approved...
► Artikel lesen
26.06.20XFRA DIVIDEND/INTEREST INFORMATION - 29.06.2020 - 31.958FOLGENDE WERTPAPIERE WERDEN AM 26.06.2020 CUM DIVIDENDE/ZINSEN UND AM 29.06.2020 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL BE 26.06.2020. THE EX-DIVIDEND/INTEREST...
► Artikel lesen
08.06.204Bio Capital: 4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin474Press Release 4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin Kyowa Kirin's first strategic investment into a Venture Capital fund Kyowa...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1